Aurinia Pharmaceuticals financials
$16.42−0.61%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY16 Dec 31 | FY15 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $283.1M | $235.1M | $175.5M | $134.0M | $45.6M | $50.1M | $318.0K | $463.0K | $173.0K | $235.0K |
| Gross profit | $250.4M | $206.9M | $161.4M | $128.4M | $44.5M | $50.1M | $318.0K | $463.0K | $173.0K | $235.0K |
| Gross margin | 88.5% | 88.0% | 91.9% | 95.8% | 97.6% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | $104.9M | -$4.7M | -$91.7M | -$111.5M | -$180.7M | -$104.3M | -$90.9M | -$55.2M | -$25.0M | -$23.7M |
| Net income | $287.2M | $5.8M | -$78.0M | -$108.2M | -$181.0M | -$102.7M | -$88.4M | -$53.1M | -$23.3M | -$18.6M |
| Net margin | 101.5% | 2.4% | −44.5% | −80.7% | −396.8% | −204.9% | −27794.0% | −11464.1% | −13465.3% | −7917.9% |
| Diluted EPS | $2.07 | $0.04 | $-0.54 | $-0.76 | $-1.40 | $-0.87 | $-0.95 | $-0.63 | $-0.66 | $-0.58 |
| EBITDA | $126.0M | $37.9M | -$80.0M | -$108.8M | -$178.0M | -$102.9M | -$89.8M | -$53.9M | -$23.7M | -$22.4M |
| Operating cash flow | $135.7M | $44.4M | -$33.5M | -$79.5M | -$157.7M | -$69.9M | -$63.6M | -$51.6M | -$18.7M | -$17.8M |
| Free cash flow | $135.4M | $44.1M | -$34.2M | -$79.8M | -$159.2M | -$77.2M | -$63.7M | -$51.7M | -$18.7M | -$17.8M |
| Diluted shares | 138.7M | 146.2M | 143.2M | 141.9M | 129.4M | 118.5M | 93.0M | 84.8M | 35.3M | 32.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $80.2M | $83.4M | $48.9M | $94.2M | $231.9M | $272.4M |
| Short-term investments | $317.8M | $275.0M | $301.6M | $295.2M | $234.2M | $126.0M |
| Total debt | $68.8M | $72.6M | $90.1M | $0.00 | $0.00 | $0.00 |
| Total assets | $751.6M | $550.6M | $548.1M | $470.9M | $543.4M | $463.7M |
| Total liabilities | $170.3M | $173.2M | $170.1M | $65.4M | $64.3M | $55.9M |
| Shareholders' equity | $581.3M | $377.5M | $378.0M | $405.4M | $479.1M | $407.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology